- Choosing the wrong pathway: Classification, intended use and claims determine which authority and evidence package apply.
- Underestimating document preparation: Missing, inconsistent or outdated records create avoidable authority questions.
- Selecting a partner for registration only: The local structure should support the company’s regulatory and commercial plans after approval.
- Assuming another market’s dossier is sufficient: UAE expectations may require local adaptations to documents, artwork or administrative evidence.
- Treating approval as the finish line: Pricing, pharmacovigilance, post-approval maintenance, coding, insurance coverage and launch planning all need ownership.
A pathway assessment and readiness review at the start can prevent expensive corrections later and create a stronger foundation for sustainable market entry.
